纽约市重症COVID-19成年患者的流行病学、临床过程与结局:前瞻性队列研究
这项前瞻性观察性队列研究在纽约市两家NewYork-Presbyterian医院开展,纳入2020年3月2日至4月1日实验室确诊COVID-19且因急性低氧性呼吸衰竭收入ICU的成年患者。257例危重症患者中,中位年龄62岁,67%为男性,82%有至少一种慢性病,46%肥胖。截至2020年4月28日,39%院内死亡,37%仍住院;79%接受有创机械通气(中位18天),66%使用血管升压药,31%接受肾脏替代治疗。多变量Cox模型显示,年龄每增加10岁、慢性心脏病、慢性肺病、白介素-6每十分位增加、D-二聚体每十分位增加与院内死亡独立相关。
要点
- 257例危重症COVID-19患者中,截至2020年4月28日39%院内死亡,37%仍住院,79%接受有创机械通气(中位18天)。
- 66%使用血管升压药,31%接受肾脏替代治疗,中位院内恶化时间为3天(IQR 1-6)。
- 多变量Cox模型:年龄每增加10岁aHR 1.31(1.09-1.57),慢性心脏病aHR 1.76(1.08-2.86),慢性肺病aHR 2.94(1.48-5.84)。
- 白介素-6每十分位增加aHR 1.11(95%CI 1.02-1.20),D-二聚体每十分位增加aHR 1.10(1.01-1.19),均与院内死亡独立相关。
- 82%患者有至少一种慢性病,最常见为高血压(63%)和糖尿病(36%),46%肥胖。
适用人群与场景
- 2020年3月2日至4月1日收入纽约市两家NewYork-Presbyterian医院(哥伦比亚大学Irving医学中心附属)的成年患者(年龄≥18岁)。
- 实验室确诊COVID-19且为危重症伴急性低氧性呼吸衰竭。
- 共1150例COVID-19住院成人中257例(22%)符合危重症标准。
研究设计与关键结果
- 前瞻性观察性队列研究,纳入257例危重症COVID-19成年患者,中位年龄62岁(IQR 51-72),171例(67%)为男性。
- 212例(82%)有至少一种慢性病,最常见为高血压162例(63%)和糖尿病92例(36%);119例(46%)肥胖。
- 截至2020年4月28日,101例(39%)院内死亡,94例(37%)仍住院。
- 203例(79%)接受有创机械通气,中位通气18天(IQR 9-28);170例(66%)使用血管升压药;79例(31%)接受肾脏替代治疗。
- 中位院内恶化时间为3天(IQR 1-6)。
- 多变量Cox模型:年龄每增加10岁aHR 1.31(1.09-1.57);慢性心脏病aHR 1.76(1.08-2.86);慢性肺病aHR 2.94(1.48-5.84);白介素-6每十分位增加aHR 1.11(95%CI 1.02-1.20);D-二聚体每十分位增加aHR 1.10(1.01-1.19)。
证据类型、等级与局限
- 证据类型:前瞻性观察性队列研究。
- 随访截至2020年4月28日右删失,确保每例患者至少28天观察。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在纽约市COVID-19住院患者中,危重症常见,且与高频率有创机械通气、肺外器官功能障碍和 substantial 院内死亡相关。
- 年龄每增加10岁、慢性心脏病、慢性肺病、较高白介素-6浓度和较高D-二聚体浓度与院内死亡独立相关,可用于床旁风险分层参考。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Over 40 000 patients with COVID-19 have been hospitalised in New York City (NY, USA) as of April 28, 2020. Data on the epidemiology, clinical course, and outcomes of critically ill patients with COVID-19 in this setting are needed.
METHODS: This prospective observational cohort study took place at two NewYork-Presbyterian hospitals affiliated with Columbia University Irving Medical Center in northern Manhattan. We prospectively identified adult patients (aged ≥18 years) admitted to both hospitals from March 2 to April 1, 2020, who were diagnosed with laboratory-confirmed COVID-19 and were critically ill with acute hypoxaemic respiratory failure, and collected clinical, biomarker, and treatment data. The primary outcome was the rate of in-hospital death. Secondary outcomes included frequency and duration of invasive mechanical ventilation, frequency of vasopressor use and renal replacement therapy, and time to in-hospital clinical deterioration following admission. The relation between clinical risk factors, biomarkers, and in-hospital mortality was modelled using Cox proportional hazards regression. Follow-up time was right-censored on April 28, 2020 so that each patient had at least 28 days of observation.
FINDINGS: Between March 2 and April 1, 2020, 1150 adults were admitted to both hospitals with laboratory-confirmed COVID-19, of which 257 (22%) were critically ill. The median age of patients was 62 years (IQR 51-72), 171 (67%) were men. 212 (82%) patients had at least one chronic illness, the most common of which were hypertension (162 [63%]) and diabetes (92 [36%]). 119 (46%) patients had obesity. As of April 28, 2020, 101 (39%) patients had died and 94 (37%) remained hospitalised. 203 (79%) patients received invasive mechanical ventilation for a median of 18 days (IQR 9-28), 170 (66%) of 257 patients received vasopressors and 79 (31%) received renal replacement therapy. The median time to in-hospital deterioration was 3 days (IQR 1-6). In the multivariable Cox model, older age (adjusted hazard ratio [aHR] 1·31 [1·09-1·57] per 10-year increase), chronic cardiac disease (aHR 1·76 [1·08-2·86]), chronic pulmonary disease (aHR 2·94 [1·48-5·84]), higher concentrations of interleukin-6 (aHR 1·11 [95%CI 1·02-1·20] per decile increase), and higher concentrations of D-dimer (aHR 1·10 [1·01-1·19] per decile increase) were independently associated with in-hospital mortality.
INTERPRETATION: Critical illness among patients hospitalised with COVID-19 in New York City is common and associated with a high frequency of invasive mechanical ventilation, extrapulmonary organ dysfunction, and substantial in-hospital mortality.
FUNDING: National Institute of Allergy and Infectious Diseases and the National Center for Advancing Translational Sciences, National Institutes of Health, and the Columbia University Irving Institute for Clinical and Translational Research.
参考来源
- Cummings MJ, Baldwin MR, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020. PMID: 32442528. doi:10.1016/S0140-6736(20)31189-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。